Dexmedetomidine intranasal - Jiangsu HengRui Medicine Co.

Drug Profile

Dexmedetomidine intranasal - Jiangsu HengRui Medicine Co.

Latest Information Update: 25 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Anxiolytics; Hypnosedatives; Imidazoles; Non-opioid analgesics; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Sedation

Most Recent Events

  • 24 Oct 2017 Chemical structure information added
  • 26 Jul 2017 Phase-I clinical trials in Sedation (In volunteers) in China (Intranasal) (NCT03293277)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top